LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Corxel Pharmaceuticals and LENZ Therapeutics released positive Phase 3 trial data for LNZ100 in treating presbyopia in China. The study showed significant improvement in vision, boosting confidence in the product's potential approval and market performance.